


DEC 22 2005



GlaxoSmithKline

**FAX****To** Attn: Examiner Deepak Rao, Group 1624**Company** USPTO**Fax** (571) 273-8300**From** Patty Wilson**Tel** 1-919-483-1007; Facsimile: 1-919-483-7977**E-mail** patricia.t.wilson@gsk.com**Date** December 22, 2005 **Pages including cover** 42**Subject** Application of: Andrews III et al.  
U.S. Serial No.: 10/070,084  
Attorney Docket No. PU3517USwGlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709Tel: 919 483 2100  
www.gsk.com**Attached:** Response under §1.111 (31 pgs);  
Supplemental IDS and 1449 (3 pgs) (in duplicate);  
Two (2) references (4 pgs);**Certificate of Transmission by Facsimile (37 CFR 1.8)**I hereby certify that this correspondence is being facsimile  
transmitted on December 22, 2005.  
Patty Wilson*Received 4 pages  
out of 42.*

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.